Thomas E Stinchcombe

Summary

Affiliation: University of North Carolina
Country: USA

Publications

  1. doi request reprint Targeted Therapies for Lung Cancer
    Thomas E Stinchcombe
    University of North Carolina at Chapel Hill, 170 Manning Drive, Physician s Office Building, 3rd Floor, Chapel Hill, NC, 27599 7305, USA
    Cancer Treat Res 170:165-82. 2016
  2. doi request reprint The Use of EGFR Tyrosine Kinase Inhibitors in EGFR Wild-Type Non-Small-Cell Lung Cancer
    Thomas E Stinchcombe
    University of North Carolina at Chapel Hill, 170 Manning Drive, Physicians Office Building 3rd floor, Chapel Hill, NC, 27599, USA
    Curr Treat Options Oncol 17:18. 2016
  3. doi request reprint Pemetrexed With Platinum Combination as a Backbone for Targeted Therapy in Non-Small-Cell Lung Cancer
    Thomas E Stinchcombe
    Division of Hematology Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC Electronic address
    Clin Lung Cancer 17:1-9. 2016
  4. pmc MEK inhibition in non-small cell lung cancer
    Thomas E Stinchcombe
    Division of Hematology and Oncology, Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, NC 27599, USA Electronic address
    Lung Cancer 86:121-5. 2014
  5. pmc Targeted therapy of advanced non-small cell lung cancer: the role of bevacizumab
    Thomas E Stinchcombe
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, NC, USA
    Biologics 1:185-94. 2007
  6. pmc Unmet needs in squamous cell carcinoma of the lung: potential role for immunotherapy
    Thomas E Stinchcombe
    Multi disciplinary Thoracic Oncology Program, University of North Carolina UNC Chapel Hill, Physicians Office Bldg CB 7305, 170 Manning Drive, 3rd Floor, Chapel Hill, NC, 27599 7305, USA
    Med Oncol 31:960. 2014
  7. doi request reprint Targeted therapies for locally advanced or metastatic squamous cell carcinoma of the lung
    Thomas E Stinchcombe
    University of North Carolina, 170 Manning Drive, POB 3rd Floor, Chapel Hill, NC, 27599 7305, USA
    Curr Treat Options Oncol 14:568-79. 2013
  8. doi request reprint A retrospective analysis of VeriStrat status on outcome of a randomized phase II trial of first-line therapy with gemcitabine, erlotinib, or the combination in elderly patients (age 70 years or older) with stage IIIB/IV non-small-cell lung cancer
    Thomas E Stinchcombe
    Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, 170 Manning Drive, Physician s Office Building, 3rd Floor, Chapel Hill, NC 27599 7305, USA
    J Thorac Oncol 8:443-51. 2013
  9. pmc Novel approaches of chemoradiotherapy in unresectable stage IIIA and stage IIIB non-small cell lung cancer
    Thomas E Stinchcombe
    Division of Hematology and Oncology, Lineberger Comprehensive Cancer Center at the University of North Carolina, Chapel Hill, North Carolina 27599 7305, USA
    Oncologist 17:682-93. 2012
  10. doi request reprint Induction chemotherapy with carboplatin, irinotecan, and paclitaxel followed by high dose three-dimension conformal thoracic radiotherapy (74 Gy) with concurrent carboplatin, paclitaxel, and gefitinib in unresectable stage IIIA and stage IIIB non-small ce
    Thomas E Stinchcombe
    Multidisciplinary Thoracic Oncology Program, 3009 Old Clinic Building CB 7305, Chapel Hill, NC 27599 7305, USA
    J Thorac Oncol 3:250-7. 2008

Detail Information

Publications61

  1. doi request reprint Targeted Therapies for Lung Cancer
    Thomas E Stinchcombe
    University of North Carolina at Chapel Hill, 170 Manning Drive, Physician s Office Building, 3rd Floor, Chapel Hill, NC, 27599 7305, USA
    Cancer Treat Res 170:165-82. 2016
    ..A phase III trial of cisplatin and gemcitabine with and without necitumumab in patients with advanced NSCLC with squamous histology demonstrated a statistically significant improvement in progression-free and overall survival. ..
  2. doi request reprint The Use of EGFR Tyrosine Kinase Inhibitors in EGFR Wild-Type Non-Small-Cell Lung Cancer
    Thomas E Stinchcombe
    University of North Carolina at Chapel Hill, 170 Manning Drive, Physicians Office Building 3rd floor, Chapel Hill, NC, 27599, USA
    Curr Treat Options Oncol 17:18. 2016
    ..I suspect that the use of EGFR TKIs in clinical use and as a comparator arm for clinical trials will continue to decline over the next several years...
  3. doi request reprint Pemetrexed With Platinum Combination as a Backbone for Targeted Therapy in Non-Small-Cell Lung Cancer
    Thomas E Stinchcombe
    Division of Hematology Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC Electronic address
    Clin Lung Cancer 17:1-9. 2016
    ..This review aims to summarize the current knowledge and future prospects of the use of pemetrexed-platinum as a backbone for combination with targeted therapies for NSCLC. ..
  4. pmc MEK inhibition in non-small cell lung cancer
    Thomas E Stinchcombe
    Division of Hematology and Oncology, Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, NC 27599, USA Electronic address
    Lung Cancer 86:121-5. 2014
    ..Other potential explanations are gene amplifications, alternative RNA splicing of genes resulting in activation of their protein products, and deregulation of noncoding RNAs and consequent altered protein expression. ..
  5. pmc Targeted therapy of advanced non-small cell lung cancer: the role of bevacizumab
    Thomas E Stinchcombe
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, NC, USA
    Biologics 1:185-94. 2007
    ..Bevacizumab is the only targeted therapy that has been shown to improve survival when combined with standard chemotherapy in the first-line setting...
  6. pmc Unmet needs in squamous cell carcinoma of the lung: potential role for immunotherapy
    Thomas E Stinchcombe
    Multi disciplinary Thoracic Oncology Program, University of North Carolina UNC Chapel Hill, Physicians Office Bldg CB 7305, 170 Manning Drive, 3rd Floor, Chapel Hill, NC, 27599 7305, USA
    Med Oncol 31:960. 2014
    ..Modulation of these pathways can lead to restored antitumor immune responses, and preliminary evidence shows that agents targeting these pathways have activity in lung cancer, including squamous NSCLC...
  7. doi request reprint Targeted therapies for locally advanced or metastatic squamous cell carcinoma of the lung
    Thomas E Stinchcombe
    University of North Carolina, 170 Manning Drive, POB 3rd Floor, Chapel Hill, NC, 27599 7305, USA
    Curr Treat Options Oncol 14:568-79. 2013
    ..The complexity of the genomics of SCC will make the development of targeted therapies challenging...
  8. doi request reprint A retrospective analysis of VeriStrat status on outcome of a randomized phase II trial of first-line therapy with gemcitabine, erlotinib, or the combination in elderly patients (age 70 years or older) with stage IIIB/IV non-small-cell lung cancer
    Thomas E Stinchcombe
    Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, 170 Manning Drive, Physician s Office Building, 3rd Floor, Chapel Hill, NC 27599 7305, USA
    J Thorac Oncol 8:443-51. 2013
    ..We performed an exploratory, blinded, retrospective analysis of plasma or serum samples collected as part of the trial to investigate the ability of VeriStrat (VS) to predict treatment outcomes...
  9. pmc Novel approaches of chemoradiotherapy in unresectable stage IIIA and stage IIIB non-small cell lung cancer
    Thomas E Stinchcombe
    Division of Hematology and Oncology, Lineberger Comprehensive Cancer Center at the University of North Carolina, Chapel Hill, North Carolina 27599 7305, USA
    Oncologist 17:682-93. 2012
    ..Adaptive radiotherapy uses changes in tumor volume to adjust the TRT treatment plan during therapy, and trials using this strategy are ongoing. Ongoing trials with proton therapy will provide initial efficacy and safety data...
  10. doi request reprint Induction chemotherapy with carboplatin, irinotecan, and paclitaxel followed by high dose three-dimension conformal thoracic radiotherapy (74 Gy) with concurrent carboplatin, paclitaxel, and gefitinib in unresectable stage IIIA and stage IIIB non-small ce
    Thomas E Stinchcombe
    Multidisciplinary Thoracic Oncology Program, 3009 Old Clinic Building CB 7305, Chapel Hill, NC 27599 7305, USA
    J Thorac Oncol 3:250-7. 2008
    ..We investigate the tolerability of gefitinib in combined modality therapy in combination with three-dimensional thoracic conformal radiation therapy (3-dimensional TCRT)...
  11. pmc Treatment outcomes of different prognostic groups of patients on cancer and leukemia group B trial 39801: induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for unresectable stage III non-small cell lung cancer
    Thomas E Stinchcombe
    University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7305, USA
    J Thorac Oncol 4:1117-25. 2009
    ..The primary objective of this analysis was to dichotomize patients into prognostic groups using factors predictive of survival and to investigate whether induction chemotherapy was beneficial in either prognostic group...
  12. pmc Phase I trial of nanoparticle albumin-bound paclitaxel in combination with gemcitabine in patients with thoracic malignancies
    Thomas E Stinchcombe
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599 7305, USA
    J Thorac Oncol 3:521-6. 2008
    ..This trial was designed to determine the maximum tolerated dose and dose limiting toxicities (DLT) of nab-paclitaxel in combination with gemcitabine...
  13. doi request reprint Gefitinib in advanced non-small cell lung cancer: does it deserve a second chance?
    Thomas E Stinchcombe
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina 27599 7305, USA
    Oncologist 13:933-44. 2008
    ..Results of recent gefitinib trials have been provocative, and suggest a role for gefitinib in the treatment of advanced NSCLC...
  14. doi request reprint Long-term follow-up of a phase I/II trial of dose escalating three-dimensional conformal thoracic radiation therapy with induction and concurrent carboplatin and paclitaxel in unresectable stage IIIA/B non-small cell lung cancer
    Thomas E Stinchcombe
    Division of Hematology Oncology, Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599 7305, USA
    J Thorac Oncol 3:1279-85. 2008
    ....
  15. pmc Phase II trial of paclitaxel and cisplatin in patients with extensive stage small cell lung cancer: Cancer and Leukemia Group B Trial 9430
    Thomas E Stinchcombe
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina 27599 7305, USA
    J Thorac Oncol 3:1301-7. 2008
    ..The results of the paclitaxel and cisplatin arm have not been reported...
  16. doi request reprint Treatment paradigms for advanced stage non-small cell lung cancer in the era of multiple lines of therapy
    Thomas E Stinchcombe
    Multidisciplinary Thoracic Oncology Program, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC 27599 7305, USA
    J Thorac Oncol 4:243-50. 2009
    ..The incremental benefit of the maintenance therapy with the targeted agent is unknown...
  17. doi request reprint Current treatments for advanced stage non-small cell lung cancer
    Thomas E Stinchcombe
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599 7305, USA
    Proc Am Thorac Soc 6:233-41. 2009
    ..Despite the improvements in care and number of therapeutic agents available, the survival for patients with advanced-stage NSCLC remains modest; novel approaches are required and participation in clinical trials should be encouraged...
  18. doi request reprint A multicenter phase II trial of carboplatin and cetuximab for treatment of advanced nonsmall cell lung cancer
    Thomas E Stinchcombe
    Multidisciplinary Thoracic Oncology Program at Lineberger Comprehensive Cancer Center at the University of North Carolina, Physicians Office Building, 3rd Floor 170 Manning Drive, CB 7305, Chapel Hill, NC 27599 7305, USA
    Cancer Invest 28:208-15. 2010
    ..To investigate the activity of carboplatin and cetuximab in NSCLC...
  19. pmc Limited-stage small cell lung cancer: current chemoradiotherapy treatment paradigms
    Thomas E Stinchcombe
    Lineberger Comprehensive Cancer Center at University of North Carolina at Chapel Hill, North Carolina 27599 7305, USA
    Oncologist 15:187-95. 2010
    ....
  20. doi request reprint Annual review of advances in lung cancer clinical research: a report for the year 2009
    Thomas E Stinchcombe
    Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina 27599 7305, USA
    J Thorac Oncol 5:935-9. 2010
    ..In limited-stage small cell lung cancer, a phase III trial compared standard and high-dose prophylactic cranial irradiation and revealed no significant difference in the rate of brain metastases between the two treatment arms...
  21. doi request reprint Maintenance therapy in advanced non-small cell lung cancer: current status and future implications
    Thomas E Stinchcombe
    Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill, NC 27599 7305, USA
    J Thorac Oncol 6:174-82. 2011
    ....
  22. doi request reprint A randomized phase II trial of first-line treatment with gemcitabine, erlotinib, or gemcitabine and erlotinib in elderly patients (age ≥70 years) with stage IIIB/IV non-small cell lung cancer
    Thomas E Stinchcombe
    Division of Hematology Oncology, Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599 7, USA
    J Thorac Oncol 6:1569-77. 2011
    ..Single-agent gemcitabine is a standard of care for elderly patients with advanced non-small cell lung cancer, but novel therapies are needed for this patient population...
  23. doi request reprint Considerations for second-line therapy of non-small cell lung cancer
    Thomas E Stinchcombe
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, 3009 Old Clinic Building CB 7305, Chapel Hill, North Carolina 27599 7305, USA
    Oncologist 13:28-36. 2008
    ..Several new agents have shown activity in phase II trials, and may be integrated into second-line therapy as single agents or in combination with current agents in the future...
  24. ncbi request reprint Drug development in patients with advanced non-small cell lung cancer and poor performance status
    Thomas E Stinchcombe
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, 3009 Old Clinic Building CB 7305, Chapel Hill, NC 27599, USA
    Semin Oncol 31:21-6. 2004
    ....
  25. ncbi request reprint Carboplatin-based chemotherapy in patients with advanced non-small cell lung cancer and a poor performance status
    Thomas E Stinchcombe
    Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, 27599, USA
    Lung Cancer 51:237-43. 2006
    ....
  26. ncbi request reprint Post-chemotherapy gross tumor volume is predictive of survival in patients with stage III non-small cell lung cancer treated with combined modality therapy
    Thomas E Stinchcombe
    Department of Hematology Oncology, University of North Carolina, Chapel Hill NC 27599 7305, USA
    Lung Cancer 52:67-74. 2006
    ..To evaluate the influence of clinical covariates, particularly pre-chemotherapy gross tumor volume (GTV), post-chemotherapy GTV, on overall survival in the treatment of stage III non-small cell lung cancer (NSCLC)...
  27. ncbi request reprint A phase I/II trial of weekly docetaxel and gefitinib in elderly patients with stage IIIB/IV non-small cell lung cancer
    Thomas E Stinchcombe
    Department of Hematology Oncology, University of North Carolina, Chapel Hill, NC 27599 7305, USA
    Lung Cancer 52:305-11. 2006
    ..The role of double agent therapy in this patient population is an area of investigation...
  28. ncbi request reprint Combined modality therapy for stage III non-small cell lung cancer
    Thomas E Stinchcombe
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina 27599 7305, USA
    Oncologist 11:809-23. 2006
    ..Thus, continued development and participation in clinical trials is crucial to further improvements in the treatment of patients with stage III disease...
  29. ncbi request reprint The role of induction therapy for resectable non-small cell lung cancer
    Thomas E Stinchcombe
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA
    Drugs 67:321-32. 2007
    ..The toxicity, efficacy and proper selection of patients for induction therapy, particularly induction chemoradiotherapy, will be assessed in ongoing and future clinical trials...
  30. doi request reprint The feasibility of adjuvant carboplatin and docetaxel in patients with curatively resected non-small cell lung cancer
    Thomas E Stinchcombe
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
    J Thorac Oncol 3:145-51. 2008
    ..Carboplatin (C) is better tolerated than cisplatin, and carboplatin-based adjuvant therapy may have better chemotherapy compliance...
  31. ncbi request reprint Nanoparticle albumin-bound paclitaxel: a novel Cremphor-EL-free formulation of paclitaxel
    Thomas E Stinchcombe
    University of North Carolina at Chapel Hill, Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, Chapel Hill, NC 27599 7305, USA
    Nanomedicine (Lond) 2:415-23. 2007
    ..The preclinical and clinical data indicate that the nab-paclitaxel formulation has significant advantages over Cremphor-EL-paclitaxel...
  32. doi request reprint Late complications of high-dose (>/=66 Gy) thoracic conformal radiation therapy in combined modality trials in unresectable stage III non-small cell lung cancer
    Carrie B Lee
    Division of Hematology Oncology, Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center at University of North Carolina at Chapel Hill, North Carolina, USA
    J Thorac Oncol 4:74-9. 2009
    ..Dose escalation of radiotherapy is one strategy used to improve locoregional control and survival, but it increases the risk of both early and late treatment related toxicities...
  33. doi request reprint Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?
    Patrick J Roberts
    Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, NC 27599 7295, USA
    J Clin Oncol 28:4769-77. 2010
    ....
  34. pmc A phase I evaluation of the combination of vinflunine and erlotinib in patients with refractory solid tumors
    Hanna K Sanoff
    Department of Medicine, Division of Hematology Oncology, School of Medicine, University of North Carolina at Chapel Hill, 170 Manning Drive, 3rd floor POB, CB 7305, Chapel Hill, NC 27599 7305, USA
    Invest New Drugs 29:978-83. 2011
    ..Epidermal growth factor receptor (EGFR) inhibition may overcome chemotherapy resistance by inhibiting important anti-apoptotic signals that are constitutively activated by an overstimulated EGFR pathway...
  35. pmc Treatment of stage IV non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines
    Mark A Socinski
    Division of Hematology Oncology, University of Pittsburgh, Pittsburgh, PA 15232, USA
    Chest 143:e341S-68S. 2013
    ..Stage IV non-small cell lung cancer (NSCLC) is a treatable, but not curable, clinical entity in patients given the diagnosis at a time when their performance status (PS) remains good...
  36. pmc A phase I trial of sorafenib combined with cisplatin/etoposide or carboplatin/pemetrexed in refractory solid tumor patients
    Janine M Davies
    Department of Medicine, Division of Hematology Oncology, University of North Carolina at Chapel Hil, USA
    Lung Cancer 71:151-5. 2011
    ..Sorafenib has demonstrated single agent activity in non-small cell (NSCLC) and small cell lung cancer (SCLC). Carboplatin/pemetrexed (CbP) and cisplatin/etoposide (PE) are commonly used in the treatment of these diseases...
  37. ncbi request reprint The emergence of a unique population in non-small cell lung cancer: systemic or loco-regional relapse following postoperative adjuvant platinum-based chemotherapy
    Mark A Socinski
    The Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599 7305, USA
    Semin Oncol 33:S32-8. 2006
    ....
  38. ncbi request reprint A phase II trial of weekly paclitaxel and gemctiabine infused at a constant rate in patients with advanced non-small cell lung cancer
    Heidi H Gillenwater
    Department of Hematology Oncology, University of Virginia Health Services, 6th Floor Multistory Building, Room 6007, Charlottesville, VA 22908, USA
    Lung Cancer 47:413-9. 2005
    ....
  39. ncbi request reprint Therapeutic advances in local-regional therapy for stage III non-small-cell lung cancer: evolving role of dose-escalated conformal (3-dimensional) radiation therapy
    Carrie B Lee
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, NC 27599, USA
    Clin Lung Cancer 8:195-202. 2006
    ..Further well-designed clinical trials that examine RT dose escalation, improved tumor targeting, altered fractionation, and incorporation of biologic agents are crucial for progress in this disease...
  40. pmc Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane) on three treatment schedules in patients with solid tumors
    Thomas E Stinchcombe
    Department of Hematology Oncology, Developmental Therapeutics Group Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA
    Cancer Chemother Pharmacol 60:759-66. 2007
    ..The purpose of this study was to determine the maximum tolerated dose (MTD) of ABI-007, on three different schedules in combination with carboplatin...
  41. ncbi request reprint Current approaches to advanced-stage non-small-cell lung cancer: first-line therapy in patients with a good functional status
    Thomas E Stinchcombe
    Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill 27599 7305, USA
    Clin Lung Cancer 7:S111-7. 2006
    ..Well-designed clinical trials with appropriate patient selection, as well as continued efforts in translational research and pharmacogenomics, are crucial for progress in this disease...
  42. ncbi request reprint Beliefs among physicians in the diagnostic and therapeutic approach to non-small cell lung cancer
    Thomas E Stinchcombe
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA
    J Thorac Oncol 2:819-26. 2007
    ..Physicians' beliefs and practice patterns may differ significantly from established guidelines. We conducted a survey to assess and compare physician beliefs against the evidence-based guidelines...
  43. ncbi request reprint The evolving role of pemetrexed (Alimta) in lung cancer
    Mark A Socinski
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA
    Semin Oncol 32:S16-22. 2005
    ..A phase II trial of single-agent pemetrexed is under way in both sensitive- and refractory-relapsed small cell lung cancer. Given the activity and excellent tolerability of pemetrexed, further studies in lung cancer are warranted...
  44. pmc Phase I trial of vinflunine and pemetrexed in refractory solid tumors
    Hanna K Sanoff
    Department of Medicine, Division of Hematology Oncology, School of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
    Invest New Drugs 29:131-6. 2011
    ..Pemetrexed has at least additive activity with other vincas. A phase I trial was undertaken to assess the safety of vinflunine and pemetrexed in patients with refractory solid tumors...
  45. ncbi request reprint Radiation-induced sarcoma after high-dose thoracic radiation therapy in non-small-cell lung cancer
    Thomas E Stinchcombe
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA
    J Clin Oncol 25:1621-3. 2007
  46. pmc Second-Line Therapy for Advanced NSCLC
    Jared M Weiss
    Lineberger Comprehensive Cancer Center at the University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599 7305, USA
    Oncologist 18:947-53. 2013
    ..The inhibitor of the EML4/ALK fusion protein, crizotinib, has recently become a standard second-line treatment for patients with the gene rearrangement and has promise for patients with the ROS1 rearrangement. ..
  47. doi request reprint KRAS mutation: should we test for it, and does it matter?
    Patrick J Roberts
    Lineberger Comprehensive Cancer Center, The University of North Carolina School of Medicine, Chapel Hill, NC 27599 7295, USA
    J Clin Oncol 31:1112-21. 2013
    ..Here we review, in the context of NSCLC, the underlying biology of KRAS mutations, the predictive value of KRAS mutations for therapeutic intervention, and the integration of KRAS mutational testing into our current clinical paradigms...
  48. ncbi request reprint High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history
    BERT H O'NEIL
    University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC 27599, USA
    J Clin Oncol 25:3644-8. 2007
    ....
  49. doi request reprint Phase I study of aurora A kinase inhibitor MLN8237 in advanced solid tumors: safety, pharmacokinetics, pharmacodynamics, and bioavailability of two oral formulations
    E Claire Dees
    UNC Lineberger Comprehensive Cancer Center, 170 Manning Drive, POB 3121, Chapel Hill, NC 27599, USA
    Clin Cancer Res 18:4775-84. 2012
    ....
  50. doi request reprint Validation of interobserver agreement in lung cancer assessment: hematoxylin-eosin diagnostic reproducibility for non-small cell lung cancer: the 2004 World Health Organization classification and therapeutically relevant subsets
    Juneko E Grilley-Olson
    Department of Medicine, Division of Hematology Oncology, and Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, NC 27599 7295, USA
    Arch Pathol Lab Med 137:32-40. 2013
    ....
  51. doi request reprint Treatment of surgically resectable non-small-cell lung cancer in elderly patients
    Benjamin E Haithcock
    Multidisciplinary Thoracic Oncology Program, Division of Cardiothoracic Surgery, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7065, USA
    Clin Lung Cancer 10:405-9. 2009
    ..This review article describes surgical resection, rationale for adjuvant therapy, and the role of molecular markers in this growing patient population...
  52. pmc A randomized phase II study of carboplatin with weekly or every-3-week nanoparticle albumin-bound paclitaxel (abraxane) in patients with extensive-stage small cell lung cancer
    Juneko E Grilley-Olson
    Lineberger Comprehensive Cancer Center at the University of North Carolina, Chapel Hill, Chapel Hill, North Carolina, USA
    Oncologist 20:105-6. 2015
    ..We hypothesized that the combination of carboplatin and nanoparticle albumin-bound paclitaxel (nab-paclitaxel) would be better tolerated. We investigated carboplatin with nab-paclitaxel on every-3-week and weekly schedules...
  53. pmc A single-arm phase II trial of pazopanib in patients with advanced non-small cell lung cancer with non-squamous histology with disease progression on bevacizumab containing therapy
    Jared M Weiss
    University of North Carolina at Chapel Hill, 170 Manning Drive, Physician s Office Building 3rd Floor, Chapel Hill, NC 27599 7305, United States
    Lung Cancer 86:288-90. 2014
    ..Mechanisms of resistance to bevacizumab include increased VEGF signaling or activation of VEGF receptors. Pazopanib is a multi-targeted VEGF receptor tyrosine kinase with single agent activity in NSCLC...
  54. pmc Alterations of LKB1 and KRAS and risk of brain metastasis: comprehensive characterization by mutation analysis, copy number, and gene expression in non-small-cell lung carcinoma
    Ni Zhao
    The Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, United States Department of Biostatistics, The Gilling School of Global Public Health, University of North Carolina at Chapel Hill, United States
    Lung Cancer 86:255-61. 2014
    ..In this study, we systematically analyzed how LKB1 and KRAS alteration, measured by mutation, gene expression (GE) and copy number (CN), are associated with brain metastasis in NSCLC...
  55. pmc CALGB 30704 (Alliance): A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small-cell lung cancer
    Rebecca S Heist
    Department of Thoracic Oncology, Massachusetts General Hospital, Boston, Massachusetts Department of Oncology, Alliance Statistics and Data Center, Duke University Medical Center, Durham, North Carolina Department of Oncology, Ohio State University Medical Center, Columbus, Ohio Department of Oncology, University of North Carolina, Chapel Hill, North Carolina Department of Oncology, Dana Farber Cancer Institute, Boston, Massachusetts Department of Oncology, Kinston Medical Specialists, P A, Kinston, North Carolina Department of Oncology, University of Chicago, Chicago, Illinois and Department of Oncology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
    J Thorac Oncol 9:214-21. 2014
    ..This trial was designed to evaluate an antivascular endothelial growth factor strategy with or without standard chemotherapy in previously treated NSCLC...
  56. doi request reprint Treatment of elderly patients with stage IV non-small-cell lung cancer
    Jared Weiss
    Multidisciplinary Thoracic Oncology Program, University of North Carolina at Chapel Hill, 170 Manning Drive, Physician s Office Building, 3rd Floor, Chapel Hill, NC 27599 7305, USA
    Expert Rev Anticancer Ther 12:111-20. 2012
    ..In the future, biochemical assessment of physiologic age may further aid this assessment...
  57. ncbi request reprint Lung cancer presenting with a solitary colon metastasis detected on positron emission tomography scan
    Thomas E Stinchcombe
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, Division of Hematology Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
    J Clin Oncol 24:4939-40. 2006
  58. doi request reprint Summary of presentations from the 46th Annual Meeting of the American Society of Clinical Oncology: focus on non-small cell lung cancer (2010)
    Thomas E Stinchcombe
    Lineberger Comprehensive Cancer Center at the University of North Carolina, Chapel Hill, North Carolina, USA
    J Thorac Oncol 6:227-32. 2011
    ..This report provides a brief overview of the presentations related to lung cancer that are relevant to clinical practice and future research...
  59. ncbi request reprint Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies
    Robert Z Orlowski
    Lineberger Comprehensive Cancer Center, Department of Medicine, University of North Carolina at Chapel Hill, 27599 7295, USA
    J Clin Oncol 20:4420-7. 2002
    ..To determine the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), and pharmacodynamics (PD) of the proteasome inhibitor bortezomib (previously known as PS-341) in patients with refractory hematologic malignancies...
  60. ncbi request reprint Third-generation chemotherapy agents in the treatment of advanced non-small cell lung cancer: a meta-analysis
    Maria Q Baggstrom
    Division of Medical Oncology, Washington University, St Louis, Missouri 63110, USA
    J Thorac Oncol 2:845-53. 2007
    ..To estimate the efficacy of third-generation (3G) chemotherapy agents (paclitaxel, docetaxel, gemcitabine, vinorelbine, and irinotecan) on response and survival in stage IIIB/IV non-small cell lung cancer (NSCLC)...
  61. ncbi request reprint Duration of first-line chemotherapy in advanced non small-cell lung cancer: less is more in the era of effective subsequent therapies
    Mark A Socinski
    J Clin Oncol 25:5155-7. 2007